Uncategorised - European Medical Journal

RSV Resistance to Nirsevimab Remains Rare in Infants

A large-scale genomic surveillance study has found that resistance to nirsevimab in infants remains rare despite widespread use.

Garlic Intake May Increase Gastritis Risk in H. pylori-Infected Individuals

Garlic intake has long been touted for its health benefits, but new research suggests it may increase the risk of atrophic gastritis in individuals with H. pylori infections.

New Topical Treatment for Primary Axillary Hyperhidrosis

The study also highlighted the psychological burden of hyperhidrosis, linking the condition to increased anxiety, depression, and impaired quality of life.

Hidden Cognitive Decline in MS: A New Concern

Cognitive decline in relapsing-remitting multiple sclerosis (RRMS) can progress independently of both relapses and MRI-detected disease activity, challenging traditional methods of monitoring MS progression, according to the results of a new study.

Deep Learning Enhances NSCLC Treatment Precision

A deep learning model offering a powerful tool for predicting how patients with advanced non-small cell lung cancer (NSCLC) will respond to immune checkpoint inhibitors (ICIs), potentially improving treatment personalization, has been newly developed.

What are the Key Predictors of Adverse Cardiovascular Outcomes with SCAD?

SCAD study flags risky blood thinners, fibromuscular dysplasia as predictors of heart complications. Urges treatment rethink.

High-Protein Diets Improve Glycaemic Control in Type 2 Diabetes

A high-protein vegan diet rich in mycoprotein improves glycaemic control in Type 2 diabetes, comparable to an omnivorous diet.

New Guidelines Improve Anaphylaxis Diagnosis and Treatment

The Clinical Support Tool is a significant advancement, integrating clear clinical criteria and epinephrine treatment guidelines.

Ultrasound Neuromodulation Offers Hope for Younger Patients with Alzheimer’s

Ultrasound therapy boosts cognition in younger Alzheimer’s patients. Study highlights TPS as a potential add-on treatment.

GLP-1 Agonists May Lower Haematologic Cancer Risk in Type 2 Diabetes

A new study shows that GLP-1 receptor agonists (GLP-1RAs) could significantly reduce the risk of developing hematologic cancers in patients with Type 2 diabetes.